temporal

Tissue is the gold standard sample for biomarker analysis to provide prognostic and predictive information and to inform treatment decisions. 

 

In this downloadable infographic, Dr Alexander Wyatt (GU cancer genomics expert) and Prof. Frédéric Bibeau (pathologist) highlight best practices to ensure sufficient quality and quantity of tissue samples for biomarker testing. 

 

Download the pdf version for the full reference list.

 

Clinical takeaways

  • Tissue is the gold standard sample for biomarker analysis to provide prognostic and predictive information and to inform treatment decisions 
  • Following pre-analytical best practices approaches ensures sufficient quality and quantity of sample for biomarker testing/molecular profiling 
  • Tissue conservation is critical – collect as much high-quality tissue as possible and carefully select biomarkers/assays to avoid tissue exhaustion 
  • Multidisciplinary communication is key for optimal sample acquisition and processing 

 

This downloadable infographic is the second in a series. View the first one here: Overcoming pre-analytical phase challenges in gastric, prostate and lung cancer.

Educational objectives

  • Know how to navigate pre-analytical phase challenges, including how to collect, store, process and prepare the samples 
  • Be able to include all relevant biomarkers in the test request and tests 
  • Understand the diagnostic modalities, and the role of biomarkers in oncology 
  • Be able to implement or improve the leading role of the pathologist on the MDT 

Dr. Wyatt is an associate professor in Urologic Sciences at the University of British Columbia, Canada. He is a senior research scientist at the Vancouver Prostate Centre and a senior scientist at BC Cancer. Dr. Wyatt has a DPhil in genetics from the University of Oxford. His research goals are to identify associations between genomic alterations and patient outcomes in metastatic prostate and bladder cancer, and to translate these findings into clinical biomarkers. Dr. Wyatt has developed novel laboratory and computational techniques to study plasma circulating tumour DNA (ctDNA). Through application of these methods to clinical trial cohorts, his team has demonstrated that ctDNA is highly representative of metastatic lesions, and that somatic alterations detected in ctDNA can help predict prostate cancer therapy resistance or response.

Frédéric Bibeau, MD, PhD, is a Professor of Pathology at the head of the Pathology Department of the Besançon University Hospital, Franche-Comté University. He is involved in translational research, in immuno-oncology of solid tumors and in gastrointestinal tumor pathology, notably colorectal cancer, both at the diagnostic and research levels. He is responsible for several long courses in pathology and molecular pathology, notably of the GI tract. Since ten years his work has been focused on rectal cancer, microsatellite unstable colorectal cancer, liver metastases after induction treatment, peritoneal carcinomatosis and predictive factors linked to targeted therapies and immunotherapy. He also involved in national and international groups specialized in rare tumors of the peritoneum. He was one of two coordinators of the BIG-RENAPE network, corresponding to a biological and clinical database dedicated to peritoneal carcinomatosis of digestive origin.

Professor Bibeau is author or co-author of 213 publications. He belongs to the board of national and international journals. He is a member of the French Society of Pathology, the International Academy of Pathology, the French Federation of Digestive Oncology (FFCD). He has been an active member of the European Society of Medical Oncology (ESMO) and the ESMO-Precision-Medicine working group.

Prof. Frédéric Bibeau has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, MSD and Sanofi. 

 

Programme summary
Other episodes in this series
Overcoming pre-analytical phase challenges in gastric, prostate and lung cancer

Overcoming pre-analytical phase challenges in gastric, prostate and lung cancer

Medical experts make recommendations for best practice

Optimising samples for biomarker testing in lung, prostate and gastric cancer

Optimising samples for biomarker testing in lung, prostate and gastric cancer

Recommendations for best practice

Current Episode
Share this programme
This educational programme is supported by an Independent Educational Grant from AstraZeneca and Amoy Diagnostics.
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
PRECISION ONCOLOGY CONNECT

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Amoy Diagnostics, Bayer and Pierre Fabre.

Meet the experts

Other programmes of interest

other Other
Oncology 
Biomarker testing in NSCLC: patient and caregiver awareness and understanding

Findings from a global survey presented in a poster at ESMO 2024

Experts
Prof. Christian Rolfo, Prof. Fernando López-Ríos, Dr. Rodrigo Paredes, Amy Moore, Anne-Marie Baird, Shani Shilo
Endorsed by
LUNGevity
Lung Cancer Europe IASLC
The Israeli Lung Cancer Foundation ISLB
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Sep 2024

Educational programme supported by an Independent Educational Grant from Bayer.
podcast Podcast
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Sep 2024

Educational programme supported by an Independent Educational Grant from Ipsen
conference-update Conference update
Oncology 
ESMO 2024: New data on GI, lung, HCC, breast and GU cancers

Renowned medical experts share their insights into new data presented at ESMO 2024

  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Sep 2024

animated-video Animated Video

Episode

1

of 1

episode
Oncology 
Precision oncology in prostate cancer: tips for optimal genomic testing

From sample collection through to diagnostic modalities 

Experts
Dr Alexander Wyatt
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Sep 2024

Educational programme supported by an Independent Educational Grant from AstraZeneca and Amoy Diagnostics.
video Video
Oncology Hemato-oncology 
Early relapsed/refractory multiple myeloma (RRMM): best practices in management

A 3-part video series on managing early RRMM from leading medical experts

Experts
Dr Elena Zamagni, Dr Fredrik Schjesvold, Dr Joseph Mikhael
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Sep 2024

Educational programme supported by an Independent Educational Grant from Menarini Stemline Oncology.
publication Publication
Oncology 
Advancing HCC management in Asia: insights from patients and HCPs

Paper published in Journal of Gastrointestinal Cancer

Experts
Prof. Chee-Kiat Tan
  • download Downloadable
    Resources
  • clock 15 MIN
  • calendar Jul 2024

This educational programme is supported by an Independent Educational Grant from Roche.